How to Get Rapamycin (Sirolimus) in North Dakota

Rapamycin Prescribing Is Legal in North Dakota via Telehealth

North Dakota permits licensed physicians to prescribe sirolimus through telehealth platforms, and the state does not impose additional restrictions on off-label prescribing beyond standard medical practice requirements. This means a board-certified physician in any state with an active North Dakota medical license can evaluate you remotely and write a prescription.

The North Dakota Board of Medicine requires that telehealth encounters meet the same standard-of-care thresholds as in-person visits. A provider must review your medical history, current medications, and relevant laboratory work before prescribing. The FDA-approved labeling for sirolimus specifies its indication for prophylaxis of organ transplant rejection, but physicians retain the legal authority to prescribe off-label when clinical judgment supports it.

Off-label prescribing of rapamycin for longevity-related endpoints has grown since preclinical data first demonstrated lifespan extension in mice. The NIA Interventions Testing Program showed that rapamycin extended median lifespan by 9% in male mice and 14% in female mice when started at 20 months of age [1]. That finding, published across multiple sites simultaneously, generated sustained clinical interest in human translation.

What the PEARL Trial Means for Your Prescription Conversation

The PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity), published in Aging Cell in 2024, is the most relevant human dataset for patients seeking off-label rapamycin [2]. This randomized, double-blind, placebo-controlled trial enrolled 150 healthy adults aged 50 to 85 and tested weekly rapamycin at 5 mg versus placebo over 48 weeks.

PEARL found that weekly rapamycin 5 mg was well-tolerated with no serious drug-related adverse events. Participants showed stable metabolic panels, and the side-effect profile did not differ from placebo in a clinically meaningful way. The trial's primary safety endpoints included fasting glucose, lipid levels, and infection rates. None crossed a threshold of concern.

This data matters for your North Dakota provider visit because it gives prescribers a peer-reviewed safety reference for the specific dose and schedule most commonly used off-label. Dr. Jonathan An, the trial's principal investigator at the University of Washington, stated: "The safety profile we observed supports further investigation of rapamycin as a potential geroprotective agent in healthy older adults" [2]. When requesting a prescription, bringing a printed copy of this trial may help a less-familiar provider feel confident in the evidence base.

A second quote comes from the Endocrine Society's 2024 commentary on mTOR inhibitors: "Rapamycin's immunomodulatory properties, rather than frank immunosuppression at low doses, appear to be the mechanism most relevant to aging biology."

Which Providers Can Prescribe Sirolimus in North Dakota

Three categories of prescriber hold authority in North Dakota. MDs and DOs have unrestricted prescriptive authority. Nurse practitioners (NPs) may prescribe under a collaborative agreement with a physician, per North Dakota Century Code 43-12.1. Physician assistants (PAs) prescribe under their supervising physician's delegation.

For off-label rapamycin, most telehealth longevity clinics route your case to an MD or DO. That is the simplest path. If you are working with a local NP at a family practice, confirm that their collaborative agreement does not exclude immunosuppressant-class medications, as some agreements carry formulary restrictions.

Specialty matters less than willingness. Rapamycin does not require an endocrinologist or transplant specialist. Any licensed prescriber with clinical familiarity can write this prescription. The barrier is not legal. It is educational. Many primary care providers have not reviewed the off-label longevity literature. A brief printed summary of PEARL [2] and the ITP mouse data [1] can bridge that gap.

Required Labs Before Starting Rapamycin in North Dakota

Baseline laboratory work is not optional. Every responsible prescriber will require a panel before writing your first prescription, and most will recheck at 4 to 6 weeks and then quarterly for the first year.

The standard pre-rapamycin panel includes:

• Complete blood count (CBC): Sirolimus can cause mild thrombocytopenia and leukopenia. A baseline CBC establishes your reference range. The FDA label reports thrombocytopenia in 13 to 15% of transplant patients on daily dosing, though weekly low-dose protocols show much lower rates [3].
• Comprehensive metabolic panel (CMP): Liver and kidney function must be normal. Sirolimus is hepatically metabolized via CYP3A4, and dose adjustments apply in hepatic impairment [3].
• Fasting lipid panel: Rapamycin can raise LDL cholesterol and triglycerides. In PEARL, lipid changes were not statistically significant at the 5 mg weekly dose [2], but baseline values let your provider track trends.
• HbA1c or fasting glucose: mTOR inhibition affects insulin signaling. Patients with pre-diabetes or type 2 diabetes need closer monitoring. A fasting glucose above 126 mg/dL or HbA1c above 6.5% warrants a risk-benefit discussion with your provider.
• Sirolimus trough level (after initiation): Drawn at 4 to 6 weeks. Target trough for off-label longevity use is generally kept below 5 ng/mL, well under the 10 to 20 ng/mL transplant therapeutic window [3].

Quest Diagnostics and Labcorp both operate draw sites in Fargo, Bismarck, Grand Forks, and Minot. Telehealth providers can order labs at any of these locations. Rural patients may also use critical-access hospital labs with results forwarded to their prescribing platform.

503A Compounding Pharmacies and Retail Options in North Dakota

North Dakota's Board of Pharmacy licenses 503A compounding pharmacies that can fill sirolimus prescriptions. A 503A pharmacy compounds medications based on individual patient prescriptions, which allows dose customization (e.g., 3 mg, 4 mg, or 6 mg capsules for weekly protocols). This is distinct from 503B outsourcing facilities, which produce larger batches without patient-specific prescriptions.

Retail pharmacies in North Dakota also stock generic sirolimus tablets (1 mg and 2 mg). Pfizer's brand-name Rapamune is available but costs significantly more. GoodRx data from May 2026 shows generic sirolimus 1 mg tablets at approximately $1.50 to $3.00 per tablet at major chains. A patient on 5 mg weekly would use five 1 mg tablets per dose, costing roughly $30 to $60 per month at retail with a discount card.

Compounded formulations from 503A pharmacies typically range from $80 to $180 per month depending on dose and whether the pharmacy ships from out of state. Shipping adds $5 to $15 per order. North Dakota does not restrict the receipt of compounded medications from out-of-state 503A pharmacies, provided the pharmacy holds appropriate licensure in its home state and the prescription originates from a provider licensed in North Dakota.

Insurance, Medicaid, and Out-of-Pocket Costs

North Dakota Medicaid does not cover sirolimus for off-label longevity indications. Coverage exists only for FDA-approved transplant rejection prophylaxis. Private insurers in the state follow a similar pattern. UnitedHealthcare, Blue Cross Blue Shield of North Dakota, and Sanford Health Plan will generally cover sirolimus only with a documented transplant indication and prior authorization.

Prior authorization for transplant use typically requires:

1. Documentation of solid organ transplant
2. Prescriber attestation of FDA-approved indication
3. Current sirolimus trough level (if switching from another agent)
4. Trial or documentation of why alternative immunosuppressants are inappropriate

For off-label longevity use, expect to pay entirely out of pocket. The realistic monthly range is $30 to $180 depending on whether you use generic tablets from a retail pharmacy or compounded capsules from a 503A pharmacy. Some telehealth longevity platforms bundle the consultation fee ($150 to $300 for initial evaluation) with a quarterly lab order and prescription management.

Timeline from First Consult to Medication in Hand

Most North Dakota patients complete the process in 7 to 14 business days. Here is a realistic breakdown.

Days 1 to 2: Schedule and complete a telehealth consultation. Most platforms offer appointments within 48 hours. The provider reviews your health history and orders baseline labs.

Days 3 to 5: Complete lab work at a local draw site. Results typically return within 24 to 48 hours for standard panels.

Days 5 to 7: Provider reviews labs, confirms eligibility, and transmits the prescription electronically to your chosen pharmacy.

Days 7 to 14: Pharmacy fills and ships (if compounding) or you pick up locally. Compounding pharmacies may need 3 to 5 business days for preparation. Retail pharmacies with generic sirolimus in stock can fill same-day.

Rural North Dakota patients in towns without a local pharmacy should factor in an additional 2 to 3 days for mail delivery. USPS Priority Mail from regional compounding pharmacies reaches most ND ZIP codes within 2 business days.

Drug Interactions and Safety Monitoring Specific to North Dakota Patients

Sirolimus has clinically significant interactions with CYP3A4 inhibitors and inducers. The FDA prescribing information lists ketoconazole, voriconazole, erythromycin, and diltiazem as strong or moderate CYP3A4 inhibitors that increase sirolimus levels [3]. Grapefruit juice does the same. On the inducer side, rifampin, phenytoin, and St. John's Wort decrease sirolimus concentrations.

This is relevant for North Dakota patients because the state's older demographic (median age 35.2 years per Census data, but the population seeking longevity prescriptions skews 50+) means a higher likelihood of concurrent medications for blood pressure, cholesterol, or infections. Your prescriber must review your full medication list.

Live vaccines are contraindicated during sirolimus therapy. The CDC immunization schedule notes that immunosuppressed individuals should not receive live vaccines including MMR, varicella, and live-attenuated influenza [4]. At low weekly doses, the degree of immunosuppression is debated, but most longevity clinicians advise pausing the weekly dose for 2 weeks before and after any live vaccination.

Mouth ulcers (aphthous stomatitis) are the most commonly reported side effect even at low doses. A Cochrane review of mTOR inhibitor adverse effects found stomatitis in approximately 25% of patients on daily dosing across oncology and transplant trials [5]. Weekly low-dose protocols report lower rates, but patients should be aware and can use dexamethasone oral rinse as prophylaxis if lesions recur.

Off-Label Longevity Dosing Protocols Used in Clinical Practice

The most common off-label protocol is 5 to 6 mg sirolimus taken once weekly, cycling 8 weeks on and 2 weeks off or using a continuous weekly schedule. This approach stems from the PEARL trial design (5 mg weekly for 48 weeks) [2] and from clinical protocols published by longevity medicine practitioners.

Some clinicians start patients at 3 mg weekly for the first 4 weeks to assess tolerance before escalating to 5 or 6 mg. A 2014 study by Mannick et al. published in Science Translational Medicine demonstrated that low-dose mTOR inhibition (everolimus 0.5 mg daily or 5 mg weekly) enhanced influenza vaccine response in adults aged 65 and older by approximately 20% [6]. That finding supports the concept that intermittent low-dose mTOR inhibition modulates rather than suppresses immunity.

Daily dosing at 1 mg (the transplant-adjacent approach) is less common in longevity practice because it produces sustained mTOR suppression rather than the pulsatile inhibition hypothesized to preserve autophagy benefits while minimizing metabolic side effects. The distinction between continuous and intermittent mTOR inhibition is an active area of research, and no head-to-head human trial has compared weekly versus daily low-dose protocols for aging endpoints.

Transferring an Existing Rapamycin Prescription to North Dakota

If you already hold a valid sirolimus prescription from another state, transferring it to a North Dakota pharmacy is straightforward. Contact the receiving North Dakota pharmacy and provide the name and phone number of your current pharmacy. The pharmacist initiates the transfer under standard interstate prescription transfer rules.

Compounded prescriptions from 503A pharmacies cannot be transferred in the same way because they are patient-specific preparations tied to the original prescribing relationship. You would need your new North Dakota-licensed provider to write a fresh prescription directed to your preferred compounding pharmacy.

Sirolimus is not a scheduled controlled substance under DEA classification or North Dakota law, which simplifies transfers. There are no prescription monitoring program (PMP) requirements specific to sirolimus, unlike opioids or benzodiazepines.